BioLineRx Gets FDA Approval for Aphexda With Filgrastim
By Chris Wack
BioLineRx said Monday that the Food and Drug Administration has approved Aphexda motixafortide in combination with filgrastim to mobilize stem cells to treat patients with multiple myeloma.
The stock was halted at $2.18 in premarket trading.
BioLineRx expects to make Aphexda available later this month.
Aphexda mobilizes hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. The success of autologous stem cell transplantation depends on adequate mobilization of stem cells during the treatment process, the Israeli biopharmaceutical company said.
The FDA approval of Aphexda is based on results from a two-part, Phase 3 trial evaluating the safety and efficacy of Aphexda plus filgrastim, compared with placebo plus filgrastim.
Multiple myeloma is an incurable blood cancer that affects certain white blood cells and is the second most-common hematologic malignancy, BioLineRx said.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 11, 2023 07:37 ET (11:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth